150
Participants
Start Date
April 10, 2023
Primary Completion Date
January 1, 2025
Study Completion Date
June 20, 2025
PD-1 inhibitor based immunotherapy
Patients received at least 4 cycles of PD-1 inhibitor-based immune monotherapy or chemoimmunotherapy. PD-1 drug selection should be limited in 4 types of PD-1 inhibitor approved by China FDA and launched in China and Opdivo or Keytruda.
Hunan cancer hospital, Changsha
Shanghai Pulmonary Hospital, Shanghai
Shanghai Pulmonary Hospital, Shanghai, China
OTHER